At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 197 enrolled
Drug / intervention
Ramucirumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy
In Brief
A Phase 2 clinical trial evaluating Ramucirumab, Placebo, and 1 other intervention for Non-small Cell Lung Cancer Metastatic. Completed, enrolled 197 participants across 15 sites.
Detailed Summary
The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy for advanced/metastatic disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer Metastatic
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartDec 2012
Primary CompletionDec 2014
Study CompletionJul 2016
TodayJul 2026
First PostedOct 10, 2012
Enrollment StartDec 1, 2012
Primary CompletionDec 1, 2014
Study CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.7 years ago
Interventions
Ramucirumabdrug
Administered IV
Placebodrug
Administered IV
Docetaxeldrug
Administered IV